Alnylam (ALNY) Pharmaceuticals announced that the European Commission has granted approval for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy as an additional indication for its orphan RNAi therapeutic AMVUTTRA. The approval broadens the indication for AMVUTTRA, which now becomes the first and only RNAi therapeutic approved by the EC for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy manifestations of hereditary transthyretin-mediated amyloidosis in adults
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam Pharma’s Strong Execution and Innovation in ATTR-CM Space Drives Positive Outlook
- Promising Market Outlook and Strong Product Pipeline Drive Buy Rating for Alnylam Pharma
- Positive Buy Rating for Alnylam Pharma Driven by Promising Clinical Data and Strategic Advancements
- Alnylam presents contemporary analysis of HELIOS-B Phase 3 study of vutrisiran
- Alnylam Pharma Re-elects Directors at Annual Meeting
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue